ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2207

Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Abstract Number: 2366

Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Abstract Number: 1543

Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus
Abstract Number: 0355

Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Abstract Number: 0490

Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality
Abstract Number: 0184

Improving Age Disparities in Contraceptive Counseling in Women with Lupus: A Quality Improvement Initiative
Abstract Number: 0418

Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice
Abstract Number: 1068

Improving Health Numeracy Literacy in Pediatric Patients with SLE
Abstract Number: 1911

Improving Healthcare Access in Underserved Brooklyn Communities: A Comprehensive Multispecialty Patient Navigator Program
Abstract Number: 1264

Improving Mental Health Care for Youth with Juvenile Dermatomyositis Through Integration of Mental Health Screening into Pediatric Rheumatology Clinic
Abstract Number: 2529

Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project
Abstract Number: 1021

Improving Preoperative Osteoporosis Screening for Orthopedic Patients
Abstract Number: 0377

Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 1078

Improving SLEDAI-2K Documentation for Childhood-Onset Systemic Lupus Erythematosus (cSLE) in a Pediatric Rheumatology Clinic Using Quality Improvement Methodology
Abstract Number: 1069

Improving Triage Accuracy of Unclear Rheumatology Referrals: A Quality Improvement Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].